Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK) HKSE

Currency In HKD

AD

Valuation

Market Cap2.62B
Enterprise Value1.49B
P/E Ratio-53.44
PEG Ratio-1.48
Price/Sales Ratio1.36
Price/Book Ratio3.79
Enterprise/Revenue-0.35
Enterprise/EBITDA2.9

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterMarch 31, 2026

Profitability

Profit Margin-0.23
Operating Margin-0.26
AD

Management Effectiveness

Return On Assets-0.06
Return On Equity-0.07

Income Statement

Revenue685.8M
Revenue/Share0.63
Gross Profit616.49M
EBITDA-81.53M
Net Income-153.36M
Diluted EPS-0.14

Balance Sheet

Total Cash1.13B
Total Cash/Share1.09
Total Debt13.23M
Total Debt/Equity0.01
Current Ratio7.46
Book Value Per Share2.05

Price History

52-Week Change-35.54
52-Week High5.29
52-Week Low2.2
Moving Average 50 Days2.49
Moving Average 200 Days2.94

Statistics

Average Volume2.64M
Shares Outstanding340M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0.05
Trailing Annual Dividend Yield0.64
Payout Ratio-0.2
Last Split FactorN/A
Last Split DateN/A
AD